
Clinical Programs
Opna Bio is dedicated to discovering and developing novel treatments for cancer patients everywhere.
We are currently validating our approach of competitive safety and efficacy through differentiated PK with our epigenetic inhibitors, OPN-6602 and OPN-2853. Both compounds are currently in early-stage clinical development in patients with hematologic malignancies.
Explore our Clinical Trials